GLP-1 Agonists: Skin Side Effects and New Hope for Inflammatory Skin Diseases

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications primarily used to manage type 2 diabetes and obesity by improving glucose metabolism and promoting satiety. While their systemic effects are well-documented, their impact on skin health, particularly regarding cutaneous adverse events and potential therapeutic benefits for inflammatory skin diseases, has been less comprehensively understood. This review specifically addresses the current understanding of dermatological effects, both negative and positive, associated with GLP-1RA use.

The review identified a spectrum of cutaneous adverse events associated with GLP-1RA use, with injection site reactions being the most common, reported in up to 20% of patients in some trials. Other reported adverse events included urticaria (hives) in 5-8% of users and angioedema (swelling) in less than 1%. However, the review also highlighted promising evidence for GLP-1RAs' anti-inflammatory properties, showing a potential 30-50% reduction in disease activity scores for conditions like psoriasis and hidradenitis suppurativa in preliminary studies. Mechanistically, GLP-1RAs appear to modulate immune responses, reducing pro-inflammatory cytokines like TNF-alpha and IL-6 by 2-fold to 3-fold in some models, suggesting a novel therapeutic pathway. This dual impact underscores the need for dermatological awareness when prescribing these widely used drugs.